title: The clinical value of serum hepatocyte growth factor levels in patients undergoing primary radiotherapy for glioma: effect on progression-free survival.
abstract: Hepatocyte growth factor (HGF) has been shown to be overexpressed in gliomas, and high-grade gliomas (glioblastoma multiforme) express more HGF than lower-grade astrocytoma, and HGF enhances their resistance to radiotherapy. To examine the effect of serum HGF levels on the likelihood of response to radiotherapy and the disease-free survival in patients with glioma, the blood samples of the patients were collected before commencing treatment and serum HGF was measured by quantitative ELISA in 48 patients with glioma grade I-IV, and all patients underwent primary conventionally fractionated radiotherapy. For statistical analysis, SPSS Version 13.0 software was used. Thirty-eight of the 48 patients had a response to treatment, and ten patients had persistent disease at 3 months. Overall, the median serum HGF level was 1,219.5 pg/ml (range 650.4-2,264.7 pg/ml). Eight patients with local failure had HGF levels >1,219.5 pg/ml, and 28 patients with response had serum HGF level of ≤ 1,219.5 pg/ml (P = 0.01). The median time to progression was 6 months in patients with HGF level of >1,219.5 pg/ml compared with 17 months in patients with HGF level of ≤ 1,219.5 pg/ml (log-rank, P = 0.041). In multivariate analysis, serum HGF, the KPS, tumour size and pathological grade, but not the patient's age, gender and oligodendroglial component influenced the progression-free survival. Elevated pre-therapeutic serum HGF levels are associated with poor response and a shorter time to progression in patients with glioma undergoing primary radiotherapy.
authors: Department of Clinical Laboratory, Tai-He Hospital, Hubei University of Medicine, 32 S. Renmin South Road, Shiyan, 442000, Hubei, China, liangqingle@gmail.com.
authors: Qing-le
authors: QL
authors: Liang
authors: Zheng-ying
authors: ZY
authors: Mo
authors: Ping
authors: P
authors: Wang
authors: Xiao
authors: X
authors: Li
authors: Zhi-xiang
authors: ZX
authors: Liu
authors: Zhang-ming
authors: ZM
authors: Zhou
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D001932:Brain Neoplasms / Q000097:blood* / Q000401:mortality* / Q000532:radiotherapy; D018572:Disease-Free Survival; D005260:Female; D005910:Glioma / Q000097:blood* / Q000401:mortality* / Q000532:radiotherapy; D017228:Hepatocyte Growth Factor / Q000097:blood*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D017228:Hepatocyte Growth Factor